Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
Sanofi Says Tolebrutinib Drug Delayed Progressive MS by 31%
FRANKFURT (Reuters) - Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a ...
BioMarin's Rare Disease Portfolio Supports a Narrow Economic Moat
With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...
Jeanne Penn joins Cambridge Healthcare Research as Vice President, US Commercial for Solici
Jeanne Penn has been appointed as Vice President, US Commercial for Solici, the strategic competitive intelligence division ...
BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy?
We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...
12 Best Biotech Stocks To Invest In According To Hedge Funds
As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1," the size of the global biotechnology industry ...
Orthopedics This Week12y
Zimmer Kills Genzyme’s Synvisc Patent
Warsaw-based Zimmer Holdings, Inc. and Boston-based Genzyme Corp have been in a Boston federal court for the last year fighting over the patent for hyaluronic acid injection treatments for arthritic ...